Table 1.

Baseline features of patients

Features	Number
Patients	64
Targets	72
Gender
Male	37
Female	27
Age
Range	33–87 years
Median	64 years
Primary targets	41
Metastatic targets	31
Treatment volume
Range	1.71–60.13 mL
Median	13.35 mL
Tracking manner
Synchrony with gold markers	45
Xsight spine	27
Isodose (%)
Range	70–94
Median	80
Dose/Fraction	6 000 cGy/3
Biologically effective dose	18 000 cGy